Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,023 across all filing types
Latest filing 2014-11-12 Major Shareholding Noti…
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
20141112 - Transparency notification of Vanguard.pdf
Major Shareholding Notification Classification · 98% confidence The document is a 'Transparency notification' received by UCB SA/NV from Vanguard Health Care Fund regarding the crossing of a large shareholding threshold (5.01%) on October 28, 2014, pursuant to Belgian law on the disclosure of large shareholdings. This type of filing specifically reports changes in significant ownership levels by external entities. This directly matches the definition for Major Shareholding Notification (MRQ). The document is short and structured like a regulatory announcement, not a comprehensive report like a 10-K or IR.
2014-11-12 English
20141112 - Déclaration de transparence de Vanguard.pdf
Major Shareholding Notification Classification · 98% confidence The document is titled "Déclaration de transparence de Vanguard Health Care Fund" and explicitly states it is a transparency declaration regarding a significant shareholding ("publicité des participations importantes"). It details that Vanguard Health Care Fund crossed the 5% threshold of voting shares in UCB SA on October 28, 2014. This content directly corresponds to the definition of a Major Shareholding Notification (MRQ), which covers changes in significant share ownership levels crossing thresholds. Although it is a regulatory filing, MRQ is the most specific category available for this type of disclosure.
2014-11-12 French
20141112 - Transparentieverklaring van Vanguard.pdf
Major Shareholding Notification Classification · 98% confidence The document is titled 'Transparantieverklaring van Vanguard Health Care Fund' and explicitly mentions a notification received regarding the crossing of a 5% ownership threshold ('de 5%-drempel heeft overschreden') by Vanguard Health Care Fund concerning UCB shares. This type of filing, which reports changes in significant share ownership by an entity, directly corresponds to the definition of a Major Shareholding Notification. The code for this is MRQ.
2014-11-12 Dutch
UCB to sell its U.S. specialty generics business Kremers Urban to Advent International and Avista Capital Partners for US$ 1,525 million
M&A Activity Classification · 99% confidence The document is a press release dated November 7, 2014, announcing a major corporate transaction: the sale of UCB's US specialty generics business (Kremers Urban) to private equity firms. It details the financial terms (US$ 1,525 million), the strategic rationale (focus on CNS and immunology core business), and mentions the expected closing date (Q1 2015). It also provides details about an upcoming conference call and references the 2014 Annual Report where the full IFRS impact will be disclosed. Since this is a specific announcement regarding a major corporate action (divestiture/sale) that impacts capital structure and business focus, it falls under the category of a significant corporate event announcement. While it mentions the Annual Report, the document itself is a press release detailing the transaction, not the full report. It is not a standard Earnings Release (ER) as it focuses on a divestiture, nor is it a Capital/Financing Update (CAP) which usually relates to raising new capital. It is a significant corporate event announcement. Given the options, the closest fit for a major, non-routine corporate transaction announcement that isn't explicitly covered by other codes (like M&A/TAR, which is usually for takeovers/mergers) is often classified under general Regulatory Filings (RNS) or sometimes as a specific type of Capital/Financing Update (CAP) if the proceeds are the main focus. However, the core event is the sale/divestiture. Since there is no specific 'Divestiture Announcement' code, and it is a formal, regulated announcement ('regulated information'), RNS is the most appropriate fallback for significant, non-standard corporate news that doesn't fit the other specific financial reporting codes. It is not a Call Transcript (CT), Earnings Release (ER), or Interim Report (IR). It is a formal announcement of a major business change.
2014-11-07 English
UCB vend Kremers Urban, sa division spécialisée dans les génériques, à Advent International et Avista Capital Partners pour US$ 1 525 millions
M&A Activity Classification · 100% confidence The document is a press release announcing a definitive agreement for the sale of a business division (Kremers Urban) by UCB to Advent International and Avista Capital Partners for $1.525 billion. This is a classic M&A (Mergers and Acquisitions) announcement. It details the strategic rationale, financial impact on the company's 2014 outlook, and mentions the involvement of financial advisors. It fits the definition of M&A Activity (TAR) perfectly.
2014-11-07 French
UCB verkoopt Kremers Urban, gespecialiseerd in generische geneesmiddelen, aan Advent International en Avista Capital Partners voor US$ 1.525 miljoen
Earnings Release Classification · 99% confidence The document is a press release dated November 7, 2014, announcing the sale of UCB's subsidiary, Kremers Urban, to Advent International and Avista Capital Partners for US$ 1.525 billion. It details the strategic rationale, financial implications (including updated 2014 outlook for core business), and includes forward-looking statements and contact information for investor relations and media. This type of announcement, detailing a major corporate transaction (divestiture/sale) and providing immediate financial context, is characteristic of a significant corporate event disclosure. While it contains financial updates, it is not the full Annual Report (10-K) or a comprehensive Interim Report (IR). It is a formal announcement of a major transaction, which often falls under general regulatory announcements or specific transaction categories. Given the options, this is a significant corporate action announcement. Since there isn't a specific 'M&A Activity' (TAR) for divestitures, and it's a formal press release about a major corporate event, it aligns best with a general regulatory announcement or a specific financing/capital event if the focus was on the cash proceeds. However, the core event is the sale/divestiture of a business unit. In many classification schemes, major corporate transactions like this are often categorized as Regulatory Filings (RNS) if a specific M&A code isn't used, or sometimes as Capital/Financing Update (CAP) due to the large cash inflow and debt reduction plans. Given the context of a major sale announcement, and lacking a specific 'Divestiture' code, RNS (Regulatory Filings) is the most appropriate general category for a major, non-periodic corporate disclosure, although TAR (M&A Activity) is also plausible if interpreted broadly. Since the text focuses heavily on the transaction details and financial impact, and it is a formal press release, I will classify it as a Regulatory Filing (RNS) as it is a material, non-periodic disclosure, or potentially TAR if M&A is interpreted to include divestitures. Given the strong focus on the sale itself, TAR (M&A Activity) is a strong candidate, but RNS is the safest fallback for material news releases. Let's re-evaluate TAR: TAR is defined as 'Merger Proposals or Takeover Bids'. This is a sale/divestiture. Since the document is a formal press release announcing a major transaction, and it is not an earnings release (ER) or a call transcript (CT), RNS is the best fit as a general material announcement, or potentially CAP if the focus was purely on the resulting capital structure change. I will select RNS as the most encompassing category for material, non-periodic news releases that don't fit elsewhere, though it is a close call with TAR if TAR is interpreted broadly to include divestitures. FY 2014
2014-11-07 Dutch

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.